Show simple item record

dc.contributor.authorFu, Siqien_US
dc.contributor.authorWu, Haijingen_US
dc.contributor.authorZhang, Huimingen_US
dc.contributor.authorLian, Christine G.en_US
dc.contributor.authorLu, Qianjinen_US
dc.date.accessioned2017-12-06T16:19:59Z
dc.date.issued2017en_US
dc.identifier.citationFu, Siqi, Haijing Wu, Huiming Zhang, Christine G. Lian, and Qianjin Lu. 2017. “DNA methylation/hydroxymethylation in melanoma.” Oncotarget 8 (44): 78163-78173. doi:10.18632/oncotarget.18293. http://dx.doi.org/10.18632/oncotarget.18293.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34493158
dc.description.abstractMelanoma is a malignant tumor of melanocytes and is considered to be the most aggressive cancer among all skin diseases. The pathogenesis of melanoma has not been well documented, which may restrict the research and development of biomarkers and therapies. To date, several genetic and epigenetic factors have been identified as contributing to the development and progression of melanoma. Besides the findings on genetic susceptibilities, the recent progress in epigenetic studies has revealed that loss of the DNA hydroxymethylation mark, 5-hydroxymethylcytosine (5-hmC), along with high levels of DNA methylation at promoter regions of several tumor suppressor genes in melanoma, may serve as biomarkers for melanoma. Moreover, 5-Aza-2′-deoxycytidine, an epigenetic modifier causing DNA demethylation, and ten-eleven translocation family dioxygenase (TET), which catalyzes the generation of 5-hmC, demonstrate therapeutic potential in melanoma treatment. In this review, we will summarize the latest progress in research on DNA methylation/hydroxymethylation in melanoma, and we will discuss and provide insight for epigenetic biomarkers and therapies for melanoma. Particularly, we will discuss the role of DNA hydroxymethylation in melanoma infiltrating immune cells, which may also serve as a potential target for melanoma treatment.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.isversionofdoi:10.18632/oncotarget.18293en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652847/pdf/en
dash.licenseLAAen_US
dc.subjectmelanomaen
dc.subject5-hmCen
dc.subject5-mCen
dc.subjectepigenetic therapyen
dc.subjectTETen
dc.titleDNA methylation/hydroxymethylation in melanomaen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorLian, Christine G.en_US
dc.date.available2017-12-06T16:19:59Z
dc.identifier.doi10.18632/oncotarget.18293*
dash.contributor.affiliatedLian, Christine


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record